78155-85-8

Basic information

• Product Name: ETHYL 5-NITRO-1H-INDAZOLE-3-CARBOXYLATE
• Synonyms: ETHYL 5-NITROINDAZOLYL-3-CARBOXYLATE;ETHYL 5-NITRO-1H-INDAZOLE-3-CARBOXYLATE;1H-Indazole-3-carboxylic acid, 5-nitro-, ethyl ester
• CAS NO: 78155-85-8
• Molecular Formula: C₁₀H₉N₃O₄
• Molecular Weight: 235.2
• Mol File: 78155-85-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 5-NITRO-1H-INDAZOLE-3-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 5-NITRO-1H-INDAZOLE-3-CARBOXYLATE(78155-85-8)
• EPA Substance Registry System: ETHYL 5-NITRO-1H-INDAZOLE-3-CARBOXYLATE(78155-85-8)

Safety Data

• Hazardous Substances Data: 78155-85-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 5-NITRO-1H-INDAZOLE-3-CARBOXYLATE is used as a building block for the synthesis of pharmaceuticals due to its potential biological activities, such as antimicrobial, antifungal, and anti-inflammatory properties. Its incorporation into drug molecules can enhance their therapeutic effects and target specific diseases.
Used in Agrochemical Industry:
In the agrochemical industry, ETHYL 5-NITRO-1H-INDAZOLE-3-CARBOXYLATE is used as a building block for the synthesis of agrochemicals. Its antimicrobial and antifungal properties make it a valuable component in developing pesticides and fungicides to protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
ETHYL 5-NITRO-1H-INDAZOLE-3-CARBOXYLATE is used as a reagent in organic synthesis for the preparation of various heterocyclic compounds. Its unique structure and functional groups make it a versatile component in the synthesis of complex organic molecules, contributing to the development of new chemical entities with potential applications in various fields.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, ETHYL 5-NITRO-1H-INDAZOLE-3-CARBOXYLATE has shown promising results for the development of new drugs. Its potential biological activities and chemical properties make it a valuable candidate for further research and development, leading to the creation of innovative therapeutic agents to address unmet medical needs.

Upstream product

• 4498-67-3 1H-Indazole-3-carboxylic acid 
• 4498-68-4 ethyl 1H-indazole-3-carboxylate 
• 64-17-5 ethanol 
• 78155-76-7 5-nitro-1H-indazole-3-carboxylic acid 

Downstream Products

• 1448314-40-6 1-(3-methoxybenzoyl)-5-nitro-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-21-3 5-amino-1-(3-methylbenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-42-8 5-acetylamino-1-(3-methylbenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-43-9 1-(3-methylbenzoyl)-5-propionylamino-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-44-0 5-butyrylamino-1-(3-methylbenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-45-1 5-benzoylamino-1-(3-methylbenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-46-2 5-(cyclohexanecarbonylamino)-1-(3-methylbenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-47-3 5-(cyclopropanecarbonylamino)-1-(3-methylbenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-48-4 5-(cyclopentanecarbonylamino)-1-(3-methylbenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-49-5 1-(3-methylbenzoyl)-5-phenylamino-1H-indazole-3-carboxylic acid ethyl ester 

Relevant articles and documents

Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase

Human neutrophil elastase (HNE) is an important therapeutic target for treatment of pulmonary diseases. Previously, we identified novel N-benzoylindazole derivatives as potent, competitive, and pseudoirreversible HNE inhibitors. Here, we report further development of these inhibitors with improved potency, protease selectivity, and stability compared to our previous leads. Introduction of a variety of substituents at position 5 of the indazole resulted in the potent inhibitor 20f (IC50 ～10 nM) and modifications at position 3 resulted the most potent compound in this series, the 3-CN derivative 5b (IC50 = 7 nM); both derivatives demonstrated good stability and specificity for HNE versus other serine proteases. Molecular docking of selected N-benzoylindazoles into the HNE binding domain suggested that inhibitory activity depended on geometry of the ligand-enzyme complexes. Indeed, the ability of a ligand to form a Michaelis complex and favorable conditions for proton transfer between Hys57, Asp102, and Ser195 both affected activity.

Pseudo-cross-conjugated mesomeric betaines and N-heterocyclic carbenes of indazole

1,2-Dimethylindazolium-3-carboxylates are pseudo-cross-conjugated mesomeric betaines (PCCMB) and derivatives of the indazole alkaloid Nigellicin. They decarboxylate on heating to give intermediary N-heterocyclic carbenes of indazole that can be trapped wi

INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.